Medical University of Vienna-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2024

  1. Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

    Journal of Personalized Medicine, Vol. 14, Núm. 2

  2. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2023

  1. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 862-875

  2. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 183, pp. 109589

  3. Prognostic factors in patients with uterine sarcoma: The SARCUT study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904

2022

  1. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

    International Journal of Gynecological Cancer